The Natural History of Patients With Pre-Existing and De Novo Inflammatory Bowel Disease After Solid Organ Transplantation: EITOS Study of GETECCU.

BACKGROUND: Limited data are available on the outcome of inflammatory bowel disease (IBD) in patients with solid organ transplantation (SOT). We describe the natural history of pre-existing IBD and de novo IBD after SOT. METHODS: This was a retrospective, multicenter study that included patients with pre-existing IBD at the time of SOT and patients with de novo IBD after SOT. The primary outcome was IBD progression, defined by escalation of medical treatment, surgical therapy, or hospitalization due to refractory IBD. Risk factors were identified using multivariate Cox proportional hazard analysis. RESULTS: A total of 177 patients (106 pre-existing IBD and 71 de novo IBD) were included. Most patients with pre-existing IBD (92.5%) were in remission before SOT. During follow-up, 32% of patients with pre-existing IBD had disease progression, with a median time between SOT and IBD progression of 2.2 (interquartile range, 1.3-4.6) years. In the de novo cohort, 55% of patients had disease progression with a median time to flare of 1.9 (interquartile range, 0.8-3.9) years after diagnosis. In the pre-existing IBD cohort, active IBD at the time of SOT (hazard ratio, 1.80; 95% confidence interval, 1.14-2.84; P = .012) and the presence of extraintestinal manifestations (hazard ratio, 3.10; 95% confidence interval, 1.47-6.54; P = .003) were predictive factors for IBD progression. CONCLUSIONS: One-third of patients with pre-existing IBD and about half of patients with de novo IBD have disease progression after SOT. Active IBD at the time of SOT and the presence of extraintestinal manifestations were identified as risk factors for IBD progression.

Initial management of intraabdominal abscesses and preventive strategies for abscess recurrence in penetrating Crohn's disease: a national multicenter study based on ENEIDA registry.

INTRODUCTION: Intra-abdominal abscesses complicating Crohn's disease (CD) are a challenging situation. Their management, during the hospitalization and after resolution, is still unclear. METHODS: Adult patients with CD complicated with intraabdominal abscess who required hospitalization were included from the prospectively maintained ENEIDA registry from GETECCU. Initial strategy effectiveness and safety to resolve abscess was assessed. Survival analysis was performed to evaluate recurrence risk. Predictive factors associated with resolution were evaluated by multivariate regression and predictive factors associated with recurrence were assessed by Cox regression. RESULTS: 520 patients from 37 Spanish hospitals were included; 322 (63%) were initially treated with antibiotics alone, 128 (26%) with percutaneous drainage, and 54 (17%) with surgical drainage. The size of the abscess was critical to the effectiveness of each treatment. In abscesses < 30mm, the antibiotic was as effective as percutaneous or surgical drainage. However, in larger abscesses, percutaneous or surgical drainage was superior. In abscesses > 50mm, surgery was superior to percutaneous drainage, although it was associated with a higher complication rate. After abscess resolution, luminal resection was associated with a lower 1-year abscess recurrence risk (HR 0.43, 95% CI 0.24-0.76). However, those patients who initiated anti-TNF therapy had a similar recurrence risk whether luminal resection had been performed. CONCLUSIONS: Small abscesses (<30mm) can be managed with antibiotics alone, while larger ones require drainage. Percutaneous drainage will be effective and safer than surgery in many cases. After discharge, anti-TNF therapy reduces abscess recurrence risk in a similar way to bowel resection.

Clinical Presentation, Management, and Evolution of Lymphomas in Patients with Inflammatory Bowel Disease: An ENEIDA Registry Study.

An increased risk of lymphoma has been described in patients with inflammatory bowel disease (IBD). The aims of our study were to determine the clinical presentation, the previous exposure to immunosuppressive and biologic therapies, and the evolution of lymphomas in patients with IBD. IBD patients with diagnosis of lymphoma from October 2006 to June 2021 were identified from the prospectively maintained ENEIDA registry of GETECCU. We identified 52 patients (2.4 cases of lymphoma/1000 patients with IBD; 95% CI 1.8-3.1). Thirty-five were men (67%), 52% had ulcerative colitis, 60% received thiopurines, and 38% an anti-TNF drug before lymphoma diagnosis. Age at lymphoma was lower in those patients treated with thiopurines (53 ± 17 years old) and anti-TNF drugs (47 ± 17) than in those patients not treated with these drugs (63 ± 12; p < 0.05). Five cases had relapse of lymphoma (1.7 cases/100 patient-years). Nine patients (17%) died after 19 months (IQR 0-48 months). Relapse and mortality were not related with the type of IBD or lymphoma, nor with thiopurines or biologic therapies. In conclusion, most IBD patients had been treated with thiopurines and/or anti-TNF agents before lymphoma diagnosis, and these patients were younger at diagnosis of lymphoma than those not treated with these drugs. Relapse and mortality of lymphoma were not related with these therapies.

Hypophosphatemic osteomalacia, a side effect of iron carboxymaltose administration.

Carboxymaltose iron (Ferinject®) is a formulation for intravenous (iv) administration, used for the treatment of iron deficiency anemia and/or iron deficiency when oral administration of iron is not effective or due to intolerance. Its safety profile is excellent with few, but not nonexistent, side effects. Hypophosphatemia has been described as one of them. It is usually mild, transient and asymptomatic. However, in some cases it may be accompanied by nausea, asthenia, in addition to muscular and neurological symptoms and hematological alterations. It is, therefore, a potentially serious adverse effect whose prevalence is unknown and which requires high clinical suspicion to be detected.

Effect of a Nutritional Support System to Increase Survival and Reduce Mortality in Patients with COVID-19 in Stage III and Comorbidities: A Blinded Randomized Controlled Clinical Trial.

The COVID-19 evolution depends on immunological capacity. The global hospital mortality rate is 15-20%, but in México it is 46%. There are several therapeutic protocols, however, integral nutrition is not considered. In this study, a Nutritional Support System (NSS) was employed to increase survival and reduce mortality in patients with stage III COVID-19. A randomized, blinded, controlled clinical trial was performed. Eighty patients (aged 30 to 75 years, both sexes) were assigned to (1) "Control Group" (CG) hospital diet and medical treatment or (2) "Intervention Group" (IG) hospital diet, medical treatment, and the NSS (vitamins, minerals, fiber, omega-3, amino acids, B-complex, and probiotics). IG significantly increased survival and reduced mortality compared to CG (p = 0.027). IG decreased progression to Mechanical Ventilation Assistance (MVA) by 10%, reduced the intubation period by 15 days, and increased survival in intubated patients by 38% compared to CG. IG showed improvement compared to CG in decrease in supplemental oxygen (p = 0.014), the qSOFA test (p = 0.040), constipation (p = 0.014), the PHQ-9 test (p = 0.003), and in the follow-up, saturation with oxygen (p = 0.030). The NSS increases survival and decreases mortality in patients with stage III COVID-19.

Evaluación de la grelina plasmática tras aplicación de neuroestimulación percutánea del dermatoma T6 en el tratamiento de la obesidad / Plasma ghrelin levels after percutaneous electrical nerve stimulation of dermatome T6 for the treatment of obesity

Introducción: Los pacientes con obesidad, con frecuencia, tienen dificultad para adherirse a una dieta baja en calorías durante largos períodos de tiempo. Una de las causas del fracaso dietético es la sensación continua de hambre. La grelina es un péptido orexígeno, secretado por células enterocromafines del fundus gástrico. El objetivo de este estudio fue analizar las variaciones de los valores plasmáticos de grelina tras PENS del dermatoma T6 asociado a dieta hipocalórica, así como la modificación del apetito y la pérdida de peso, comparándolo con un grupo control en el que solo se pautó una dieta hipocalórica. Material y métodos: Realizamos un estudio prospectivo no aleatorizado, incluyendo 20 pacientes sometidos a PENS del dermatoma T6, asociado a dieta hipocalórica, como tratamiento previo a ser sometidos a una técnica de cirugía bariátrica y con el fin de reducir peso (grupo 1), y 20 pacientes a los que se les pautó exclusivamente dieta hipocalórica previa a la intervención quirúrgica (grupo 2). En el grupo 1 se analizaron los niveles de grelina plasmática en 5 momentos diferentes del procedimiento: antes de realizar la primera sesión de PENS (muestra 1a), al finalizar la primera sesión de PENS (muestra 1b), antes de realizar la última sesión de PENS (muestra 2a), al finalizar la última sesión de PENS (muestra 2b) y un mes después de haber finalizado el tratamiento (muestra 3). En el grupo 2 se obtuvieron solo 2 muestras, antes de comenzar la dieta (muestra 1) y tras 12 semanas de dieta (muestra 2). Resultados: Tras 12 semanas de tratamiento se observó una pérdida de IMC del 8,42 ± 2,6% en el grupo 1 y del 1,32 ± 0,98% en el grupo 2 (p = 0,007). En el grupo 1 se apreció un descenso significativo de los valores de grelina entre las muestras 1a y 2a, y entre las muestras 1a y 3. En el grupo 2 se observó un aumento no significativo de los niveles de grelina entre las muestras 1 y 2. Conclusión: El PENS del dermatoma T6 se asoció con una disminución en los valores de grelina plasmática. Esta terapia, asociada a una dieta hipocalórica, consigue una pérdida de IMC superior al 8% en 12 semanas de tratamiento

Introduction: Obese patients often find it difficult to adhere to long-term low-calorie diets. One of the reasons for dietary failure is the permanent feeling of hunger. Ghrelin is an orexigenic hormone, secreted by enterochromaffin cells in the gastric fundus. The aim of this study was to analyze changes in plasma ghrelin levels after PENS of dermatome T6 associated to a low-calorie diet, as well as changes in appetite and weight loss, as compared to a control group on a low-calorie alone. Material and methods: A prospective, non-randomized study was conducted including 20 patients who underwent PENS of dermatome T6 associated to a low-calorie diet before undergoing bariatric surgery to lose weight (Group 1), and 20 patients who were only prescribed a low-calorie diet before surgery (Group 2). In Group 1, plasma ghrelin levels were measured at 5 timepoints: before the first PENS session (Sample 1a); after the first PENS session (Sample 1b); before the last PENS session (Sample 2a); after the last PENS session (Sample 2b); and one month after treatment completion (Sample 3). In Group 2, only two samples were collected: before the start of the diet (Sample 1) and after 12 weeks of diet (Sample 2). Results: After 12 weeks of treatment, BMI decreases of 8.42% ± 2.6% and 1.32% ± 0.98% were seen in Group 1 and Group 2 respectively (p = 0.007). A significant decrease was seen in ghrelin levels between samples 1a and 2a, and between samples 1a and 3. In Group 2, a non-significant increase was seen in ghrelin levels. Conclusion: PENS of dermatome T6 was associated to decreased plasma ghrelin levels. This therapy, associated to a low-calorie diet, achieves a BMI reduction greater than 8% after 12 weeks of treatment

Plasma ghrelin levels after percutaneous electrical nerve stimulation of dermatome T6 for the treatment of obesity. / Evaluación de la grelina plasmática tras aplicación de neuroestimulación percutánea del dermatoma T6 en el tratamiento de la obesidad.

INTRODUCTION: Obese patients often find it difficult to adhere to long-term low-calorie diets. One of the reasons for dietary failure is the permanent feeling of hunger. Ghrelin is an orexigenic hormone, secreted by enterochromaffin cells in the gastric fundus. The aim of this study was to analyze changes in plasma ghrelin levels after PENS of dermatome T6 associated to a low-calorie diet, as well as changes in appetite and weight loss, as compared to a control group on a low-calorie alone. MATERIAL AND METHODS: A prospective, non-randomized study was conducted including 20 patients who underwent PENS of dermatome T6 associated to a low-calorie diet before undergoing bariatric surgery to lose weight (Group 1), and 20 patients who were only prescribed a low-calorie diet before surgery (Group 2). In Group 1, plasma ghrelin levels were measured at 5 timepoints: before the first PENS session (Sample 1a); after the first PENS session (Sample 1b); before the last PENS session (Sample 2a); after the last PENS session (Sample 2b); and one month after treatment completion (Sample 3). In Group 2, only two samples were collected: before the start of the diet (Sample 1) and after 12 weeks of diet (Sample 2). RESULTS: After 12 weeks of treatment, BMI decreases of 8.42%±2.6% and 1.32%±0.98% were seen in Group 1 and Group 2 respectively (p=0.007). A significant decrease was seen in ghrelin levels between samples 1a and 2a, and between samples 1a and 3. In Group 2, a non-significant increase was seen in ghrelin levels. CONCLUSION: PENS of dermatome T6 was associated to decreased plasma ghrelin levels. This therapy, associated to a low-calorie diet, achieves a BMI reduction greater than 8% after 12 weeks of treatment.

[CUN-BAE formula and biochemical factors as predictive markers of obesity and cardiovascular disease in patients before and after sleeve gastrectomy]. / Fórmula CUN-BAE y factores bioquímicos como marcadores predictivos de obesidad y enfermedad cardiovascular en pacientes pre y post gastrectomía vertical.

INTRODUCTION: Body Mass Index (BMI) is one of the most used parameters in bariatric surgery. However, it does not discriminate the weight associated with adiposity. CUN-BAE formula is an equation that calculates Body Fat Percentage or adiposity, based on easily available values (age, sex and BMI). With this new classification many of the subjects that was considered normal weight or overweight (BMI ≤30 kg/m2) really have a higher adiposity and they have comorbidities associated with obesity. The objective of this study is to evaluate the adiposity by formula CUN-BAE as a predictive marker of cardiovascular risk in morbidly obese patients before and after sleeve gastrectomy. MATERIAL AND METHODS: We performed a retrospective observational study of women that were intervened with sleeve gastrectomy, between 2007 and 2012 at the Universitary General Hospital of Elche. The adiposity was calculated by formula CUN-BAE preoperatively and 12 months after surgery. These values were correlated with different metabolic and cardiovascular risk parameters. RESULTS: 50 women were studied. Preoperatively, the mean BMI was 50.4 ± 7 kg/m2 and adiposity 54.8 ± 3%. One year after surgery, the mean BMI was 27.7 ± 3 and adiposity 39.4 ± 4%. The adiposity was significantly correlated with 3 biochemical factors associated with increased cardiovascular risk (cortisol, vitamin D and ratio TG/HDL). CONCLUSION: Adiposity, according to the formula CUNBAE, and biochemical analysis of predictive factors of obesity together represent useful tools for assessing the risk of cardiovascular disease after sleeve gastrectomy.

Introducción: Introducción: El Índice de Masa Corporal (IMC) es uno de los parámetros más utilizados en cirugía bariátrica. Sin embargo, no discrimina el peso asociado a adiposidad. La fórmula CUN-BAE es una ecuación que permite calcular el Porcentaje de Grasa Corporal (PGC) o adiposidad, basándose en valores fáciles de disponer (edad, sexo e IMC). Con esta nueva clasificación muchos de los sujetos considerados con normopeso o sobrepeso (IMC ≤30 kg/m2) en realidad tienen un PGC alto y presentan comorbilidades asociadas a la obesidad. El objetivo de este estudio es evaluar PGC cuantificado mediante fórmula CUN-BAE como marcador predictivo de riesgo cardiovascular en pacientes obesos mórbidos, antes y después de ser sometidos a Gastrectomía Vertical (GV). Material y métodos: Realizamos un estudio observacional retrospectivo de mujeres intervenidas de GV entre 2007 y 2012 en el Hospital General Universitario de Elche, calculando el PGC mediante la fórmula CUN-BAE de forma preoperatoria y 12 meses tras la intervención. Se correlacionaron estos valores con diferentes parámetros metabólicos y de riesgo cardiovascular. Resultados: Se estudiaron 50 mujeres. Preoperatoriamente, el IMC medio de 50,4 ± 7,4 kg/m2 y PGC del 54,8 ± 3%. Al año de la intervención, el IMC medio era de 27,7 ± 2,6 y el PGC 39,4 ± 3,7%. La PGC se correlacionó significativamente con 3 factores bioquímicos asociados con mayor riesgo cardiovascular (cortisol, vitamina D y cociente TG/HDL). Conclusión: la adiposidad, según la fórmula CUN-BAE, y el análisis de factores bioquímicos predictivos de obesidad, de forma conjunta suponen herramientas útiles para valorar el riesgo de enfermedad cardiovascular, después de GV.

Fórmula CUN-BAE y factores bioquímicos como marcadores predictivos de obesidad y enfermedad cardiovascular en pacientes pre y post gastrectomía vertical / Cun-bae formula and biochemical factors as predictive markers of obesity and cardiovasclar disease in patients before and after sleeve gastrectomy

Introducción: El Índice de Masa Corporal (IMC) es uno de los parámetros más utilizados en cirugía bariátrica. Sin embargo, no discrimina el peso asociado a adiposidad. La fórmula CUN-BAE es una ecuación que permite calcular el Porcentaje de Grasa Corporal (PGC) o adiposidad, basándose en valores fáciles de disponer (edad, sexo e IMC). Con esta nueva clasificación muchos de los sujetos considerados con normopeso o sobrepeso (IMC ≤ 30 kg/m2 ) en realidad tienen un PGC alto y presentan comorbilidades asociadas a la obesidad. El objetivo de este estudio es evaluar PGC cuantificado mediante fórmula CUN-BAE como marcador predictivo de riesgo cardiovascular en pacientes obesos mórbidos, antes y después de ser sometidos a Gastrectomía Vertical (GV). Material y métodos: Realizamos un estudio observacional retrospectivo de mujeres intervenidas de GV entre 2007 y 2012 en el Hospital General Universitario de Elche, calculando el PGC mediante la fórmula CUN-BAE de forma preoperatoria y 12 meses tras la intervención. Se correlacionaron estos valores con diferentes parámetros metabólicos y de riesgo cardiovascular. Resultados: Se estudiaron 50 mujeres. Preoperatoriamente, el IMC medio de 50,4 ± 7,4 kg/m2 y PGC del 54,8 ± 3%. Al año de la intervención, el IMC medio era de 27,7 ± 2,6 y el PGC 39,4 ± 3,7%. La PGC se correlacionó significativamente con 3 factores bioquímicos asociados con mayor riesgo cardiovascular (cortisol, vitamina D y cociente TG/HDL). Conclusión: la adiposidad, según la fórmula CUN-BAE, y el análisis de factores bioquímicos predictivos de obesidad, de forma conjunta suponen herramientas útiles para valorar el riesgo de enfermedad cardiovascular, después de GV (AU)

Introduction: Body Mass Index (BMI) is one of the most used parameters in bariatric surgery. However, it does not discriminate the weight associated with adiposity. CUN- BAE formula is an equation that calculates Body Fat Percentage or adiposity, based on easily available values (age, sex and BMI). With this new classification many of the subjects that was considered normal weight or overweight (BMI ≤ 30 kg/m2 ) really have a higher adiposity and they have comorbidities associated with obesity. The objective of this study is to evaluate the adiposity by formula CUN-BAE as a predictive marker of cardiovascular risk in morbidly obese patients before and after sleeve gastrectomy. Material and methods: We performed a retrospective observational study of women that were intervened with sleeve gastrectomy, between 2007 and 2012 at the Universitary General Hospital of Elche. The adiposity was calculated by formula CUN-BAE preoperatively and 12 months after surgery. These values were correlated with different metabolic and cardiovascular risk parameters. Results: 50 women were studied. Preoperatively, the mean BMI was 50.4 ± 7 kg/m2 and adiposity 54.8 ± 3%. One year after surgery, the mean BMI was 27.7 ± 3 and adiposity 39.4 ± 4%. The adiposity was significantly correlated with 3 biochemical factors associated with increased cardiovascular risk (cortisol, vitamin D and ratio TG/HDL). Conclusion: Adiposity, according to the formula CUNBAE, and biochemical analysis of predictive factors of obesity together represent useful tools for assessing the risk of cardiovascular disease after sleeve gastrectomy (AU)